CD19 and lymphoma: Currently, the only TandAb in active clinical testing is AFM13, an NK-cell redirecting anti-CD30/CD16A TandAb for the treatment of lymphomas, while the anti-CD19/CD3 AFM11was suspended due to side effects (NCT02106091).